Fresenius Medical Care (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Fresenius Medical Care (NYSE:FMS) in a report issued on Tuesday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial lifted their target price on Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a research report on Wednesday, May 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $32.25.

Fresenius Medical Care Stock Up 0.6 %

Fresenius Medical Care stock opened at $19.51 on Tuesday. The stock’s fifty day moving average is $20.83 and its two-hundred day moving average is $20.23. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.50 and a quick ratio of 1.14. Fresenius Medical Care has a 1-year low of $16.37 and a 1-year high of $27.72. The stock has a market cap of $11.45 billion, a PE ratio of 21.92, a P/E/G ratio of 1.04 and a beta of 0.93.

Fresenius Medical Care (NYSE:FMS) last posted its earnings results on Tuesday, May 7th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.10. Fresenius Medical Care had a return on equity of 5.29% and a net margin of 2.48%. The business had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.15 billion. On average, sell-side analysts expect that Fresenius Medical Care will post 1.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care

Several institutional investors have recently added to or reduced their stakes in the stock. Bruce G. Allen Investments LLC purchased a new stake in Fresenius Medical Care in the 4th quarter valued at approximately $31,000. Hartford Financial Management Inc. boosted its holdings in Fresenius Medical Care by 98.8% in the 4th quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock valued at $35,000 after purchasing an additional 839 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Fresenius Medical Care by 349.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,314 shares of the company’s stock valued at $48,000 after purchasing an additional 1,799 shares in the last quarter. GAMMA Investing LLC purchased a new stake in Fresenius Medical Care in the 4th quarter valued at approximately $67,000. Finally, Assetmark Inc. boosted its holdings in Fresenius Medical Care by 169.9% in the 4th quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock valued at $87,000 after purchasing an additional 2,630 shares in the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.